Patents by Inventor Yen-Hsing LI

Yen-Hsing LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSIS
    Publication number: 20240165279
    Abstract: Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF); it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
    Type: Application
    Filed: December 22, 2023
    Publication date: May 23, 2024
    Inventors: Philip Stewart Low, Suraj U. Hettiarachchi, Yen-Hsing Li, Jyoti Roy
  • Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis
    Patent number: 11890357
    Abstract: Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: February 6, 2024
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Suraj U. Hettiarachchi, Yen-Hsing Li, Jyoti Roy
  • FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSIS
    Publication number: 20230033291
    Abstract: Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP). this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
    Type: Application
    Filed: June 29, 2022
    Publication date: February 2, 2023
    Inventors: Philip Stewart Low, Suraj U. Hettiarachchi, Yen-Hsing Li, Jyoti Roy
  • Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis
    Patent number: 11426472
    Abstract: Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: August 30, 2022
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Suraj U. Hettiarachchi, Yen-Hsing Li, Jyoti Roy
  • FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSIS
    Publication number: 20220001037
    Abstract: Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP), this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.
    Type: Application
    Filed: October 15, 2019
    Publication date: January 6, 2022
    Inventors: Philip Stewart Low, Suraj U. Hettiarachchi, Yen-Hsing Li, Jyoti Roy
  • Base oil and lubricant oil composition including the same
    Patent number: 11111450
    Abstract: A base oil includes an ester compound obtained by reacting a fatty acid component and a monohydric alcohol component. The fatty acid component includes a C4-C28 fatty acid. The monohydric alcohol component includes at least one C4-C22 straight chain monohydric alcohol and at least one C4-C22 branched chain monohydric alcohol. A lubricant oil composition including the base oil is also disclosed.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: September 7, 2021
    Assignee: Patech Fine Chemicals Co., Ltd.
    Inventors: Wei-Chieh Liang, Yen-Hsing Li, Hsu-Hua Tang, Jung-Tsung Hung, Jeng-Shiang Tsaih
  • BASE OIL AND LUBRICANT OIL COMPOSITION INCLUDING THE SAME
    Publication number: 20200148966
    Abstract: A base oil includes an ester compound obtained by reacting a fatty acid component and a monohydric alcohol component. The fatty acid component includes a C4-C28 fatty acid. The monohydric alcohol component includes at least one C4-C22 straight chain monohydric alcohol and at least one C4-C22 branched chain monohydric alcohol. A lubricant oil composition including the base oil is also disclosed.
    Type: Application
    Filed: November 7, 2019
    Publication date: May 14, 2020
    Inventors: Wei-Chieh LIANG, Yen-Hsing LI, Hsu-Hua TANG, Jung-Tsung HUNG, Jeng-Shiang TSAIH